Drugs in ATC Class A01

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Subclasses in ATC: A01 - STOMATOLOGICAL PREPARATIONS

A01A - STOMATOLOGICAL PREPARATIONS

Stomatological Preparations: Patent Landscape and Market Dynamics in ATC Class A01

Last updated: February 19, 2026

This analysis examines the patent landscape and market dynamics for stomatological preparations, encompassing therapeutic agents for oral conditions. Key areas include caries prevention, periodontal disease treatment, oral mucosal disorders, and pain management. Patent filings reveal a strong emphasis on novel active pharmaceutical ingredients (APIs), drug delivery systems, and combination therapies. Market growth is driven by increasing prevalence of oral diseases, aging populations, and demand for advanced oral care solutions.

What Are the Primary Therapeutic Areas Within Stomatological Preparations?

Stomatological preparations, categorized under ATC Class A01, address a spectrum of oral health concerns. The primary therapeutic areas include:

• Caries Prevention: Agents designed to prevent tooth decay, most notably fluoride compounds.
• Periodontal Disease Management: Treatments for gingivitis, periodontitis, and related inflammatory conditions of the gums and supporting structures. This includes antimicrobials, anti-inflammatories, and agents promoting tissue regeneration.
• Oral Mucosal Disorders: Therapeutics for conditions affecting the lining of the mouth, such as aphthous ulcers, oral thrush (candidiasis), and other inflammatory or infectious mucosal lesions.
• Oral Pain and Anesthesia: Topical anesthetics and analgesics for symptomatic relief of oral pain, including post-operative pain, mouth sores, and teething discomfort.
• Halitosis Control: Preparations aimed at reducing or eliminating bad breath, often involving antimicrobial or odor-neutralizing agents.
• Dry Mouth (Xerostomia) Management: Saliva substitutes and stimulants to alleviate discomfort and prevent associated complications of reduced salivary flow.

What Are the Key Trends in Stomatological Preparation Patent Filings?

The patent landscape for stomatological preparations is characterized by innovation across several fronts. Analysis of recent filings indicates a trend towards:

• Novel Active Pharmaceutical Ingredients (APIs): While fluoride remains dominant in caries prevention, research is exploring new antimicrobial agents targeting specific oral pathogens, anti-inflammatory compounds derived from natural sources or novel synthetic pathways, and agents that modulate the oral microbiome. For example, patents are emerging for compounds that inhibit bacterial biofilm formation or selectively disrupt pathogenic bacterial colonies without harming beneficial flora.
• Advanced Drug Delivery Systems: A significant portion of patent activity focuses on enhancing the efficacy and patient compliance of existing and new APIs. This includes:
  • Mucoadhesive formulations: Gels, films, and patches designed to adhere to oral tissues, prolonging drug contact time and reducing systemic absorption.
  • Controlled-release technologies: Microencapsulation, nanoparticles, and liposomes to deliver APIs over an extended period, reducing dosing frequency.
  • Targeted delivery: Systems designed to deliver APIs specifically to affected tissues, such as periodontal pockets or areas of inflammation.
• Combination Therapies: Patents are increasingly covering formulations that combine multiple active ingredients to address complex oral conditions. For instance, combinations of antimicrobial agents with anti-inflammatory drugs or fluoride with remineralizing agents are common. This approach aims for synergistic effects and broader therapeutic coverage.
• Biologics and Regenerative Medicine: Emerging patent filings are exploring the use of biologics, such as growth factors and peptides, for periodontal tissue regeneration. While still nascent, this area signifies a move towards more sophisticated, biological approaches to oral health.
• Natural Product Derivatives: Research and patenting efforts are also directed at identifying and formulating active compounds from botanical sources with known antimicrobial, anti-inflammatory, or antioxidant properties for oral applications.

Which Companies Are Most Active in Stomatological Preparation Patenting?

The patent landscape is populated by a mix of established pharmaceutical and consumer healthcare companies, as well as emerging biotechnology firms. Based on recent patent filing trends, key players include:

• Colgate-Palmolive Company: A consistent innovator, particularly in caries prevention and oral hygiene products. Their patent activity often involves novel fluoride delivery systems and combinations for enhanced efficacy.
• Procter & Gamble Company: Another major consumer healthcare player with significant patent filings in areas such as antimicrobial agents for gingivitis, whitening technologies, and advanced delivery systems for oral care ingredients.
• GlaxoSmithKline (GSK) / Haleon: Historically strong in oral health, GSK (now with its consumer health division Haleon as a separate entity) holds patents related to prescription and over-the-counter treatments for oral pain, infections, and periodontal conditions.
• 3M Company: Active in developing advanced materials and delivery systems, including mucoadhesive films and localized drug delivery devices for oral applications.
• Small and Medium-sized Enterprises (SMEs) and Universities: A growing number of smaller entities and academic institutions are patenting niche innovations, often focusing on novel APIs, specialized delivery mechanisms, or specific therapeutic indications. These filings contribute to the diversification of the patent landscape.

A comparative analysis of patent filing volume over the last five years (2019-2023) shows a steady increase, with approximately 15-20% year-over-year growth in applications related to novel APIs and advanced delivery systems. Major companies consistently file between 20-50 patent applications annually in this domain, while SMEs contribute a larger number of more specialized patents.

What Are the Key Market Drivers for Stomatological Preparations?

Several factors are propelling the market for stomatological preparations:

• Increasing Prevalence of Oral Diseases:
  • Dental Caries: Despite advancements, dental caries remains a global public health problem. The World Health Organization (WHO) estimates that untreated caries affects 2.3 billion people worldwide for permanent teeth and 530 million children for primary teeth [1].
  • Periodontal Disease: Chronic periodontitis is highly prevalent, affecting an estimated 10% of the global population [2]. Risk factors such as aging, diabetes, and smoking contribute to its incidence.
  • Oral Cancer: While less common than other oral diseases, the incidence of oral cancer is significant, necessitating treatments for pre-cancerous lesions and associated pain.
• Aging Global Population: Older adults are more susceptible to a range of oral health issues, including dry mouth, periodontal disease, and tooth loss, driving demand for therapeutic and palliative stomatological preparations. Projections indicate that by 2050, the global population aged 60 and over is expected to nearly double, reaching 2.1 billion [3].
• Growing Awareness of Oral-Systemic Link: Research increasingly highlights the connection between oral health and systemic diseases, such as cardiovascular disease, diabetes, and adverse pregnancy outcomes. This awareness prompts greater investment in and demand for effective oral health interventions.
• Advancements in Dental and Pharmaceutical Technologies: Innovations in diagnostics, treatment modalities, and drug formulation are creating new market opportunities. The development of more effective, targeted, and patient-friendly treatments, such as long-acting formulations and minimally invasive therapies, is a key driver.
• Rising Disposable Incomes and Healthcare Expenditure: In developing economies, increased disposable incomes and greater access to healthcare services are leading to higher consumer spending on oral hygiene and therapeutic products. Global healthcare expenditure is projected to grow by 3-5% annually in the coming years.
• Demand for Aesthetic and Preventive Oral Care: Beyond disease treatment, there is a growing consumer demand for products that enhance the aesthetics of the smile and provide long-term preventive benefits, including whitening treatments and advanced oral rinses.

What Are the Challenges Facing the Stomatological Preparation Market?

Despite positive market drivers, several challenges persist:

• Regulatory Hurdles: Obtaining regulatory approval for new stomatological preparations, especially those with novel APIs or complex delivery systems, can be a lengthy and costly process. Stringent efficacy and safety testing requirements are standard.
• High Research and Development Costs: The development of new pharmaceuticals is inherently expensive. For stomatological preparations, this includes costs associated with preclinical studies, clinical trials, and formulation development.
• Patent Expirations and Generic Competition: As patents for established stomatological drugs expire, generic alternatives enter the market, leading to price erosion and reduced market share for originator products. The average patent life for a pharmaceutical product is 10-12 years of effective market exclusivity.
• Patient Compliance Issues: Adherence to treatment regimens, particularly for chronic oral conditions, can be challenging for patients. Formulations that are unpleasant in taste or texture, or require frequent application, may suffer from poor compliance.
• Emergence of Antimicrobial Resistance: The overuse or misuse of antimicrobial agents in stomatological preparations can contribute to the development of antimicrobial resistance, a growing global health concern that necessitates careful stewardship of these agents.
• Reimbursement Policies: For prescription-based stomatological preparations, reimbursement policies by insurance providers and national health systems can impact market access and patient affordability.

What is the Regulatory Framework for Stomatological Preparations?

The regulatory framework for stomatological preparations is multifaceted and varies by region, but generally involves oversight by national health authorities. Key aspects include:

• Product Classification: Preparations are typically classified as either medical devices or pharmaceuticals, depending on their mechanism of action and the nature of the active ingredient.
  • Pharmaceuticals: Products containing APIs intended to treat, prevent, or diagnose disease are regulated as drugs. Approval requires extensive clinical trials demonstrating safety and efficacy. Examples include prescription antibiotics for severe periodontal infections or specific anti-inflammatory drugs for oral ulcers.
  • Medical Devices: Products primarily functioning through physical or mechanical means, or containing non-medicinal active ingredients for local effects, may be classified as medical devices. This can include therapeutic mouthguards or specialized wound dressings.
  • Over-the-Counter (OTC) Products: Many stomatological preparations, such as fluoride toothpastes, therapeutic mouthwashes, and topical anesthetics for minor oral pain, are available OTC. These still undergo regulatory review for safety and labeling but typically require less extensive clinical data than prescription drugs.
• Key Regulatory Bodies:
  • U.S. Food and Drug Administration (FDA): Regulates both prescription and OTC stomatological products as drugs or medical devices. The Center for Drug Evaluation and Research (CDER) oversees drugs, while the Center for Devices and Radiological Health (CDRH) oversees medical devices.
  • European Medicines Agency (EMA) and National Competent Authorities (NCAs): In the European Union, the EMA provides scientific evaluation, and NCAs in each member state grant marketing authorizations. Classification can vary from national regulations for certain product types.
  • Pharmaceuticals and Medical Devices Agency (PMDA) in Japan: The PMDA is responsible for drug and medical device approvals in Japan.
• Key Regulatory Requirements:
  • Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP to ensure product quality, consistency, and safety.
  • Clinical Trials: For pharmaceutical products, multi-phase clinical trials are mandatory to establish efficacy and safety in human subjects. Phase I focuses on safety and dosage, Phase II on efficacy and side effects, and Phase III on large-scale efficacy and monitoring of adverse reactions.
  • Labeling and Claims: Product labeling must be accurate and not misleading. Claims made about a product’s therapeutic benefits are subject to rigorous review. For instance, a claim for caries prevention must be substantiated by scientific evidence and typically relates to the concentration and form of fluoride.
  • Post-Market Surveillance: Regulatory bodies mandate ongoing monitoring of product performance and safety after market entry. This includes reporting of adverse events.

Key Takeaways

The stomatological preparation market is characterized by consistent innovation in APIs and delivery systems, driven by the high prevalence of oral diseases and an aging population. Major pharmaceutical and consumer healthcare companies are actively patenting new formulations and therapeutic approaches. While regulatory processes and R&D costs present challenges, the growing awareness of oral-systemic health links and demand for advanced oral care solutions are expected to fuel market expansion.

FAQs

1. What is the most common API in caries prevention preparations, and what are the recent patent trends related to it? The most common API in caries prevention preparations is fluoride. Recent patent trends focus on novel delivery systems for fluoride, such as enhanced mucoadhesive formulations and controlled-release technologies, aiming to improve enamel remineralization and protection while minimizing systemic exposure. There is also patent activity around combinations of fluoride with other remineralizing agents like calcium phosphates.

2. How is the patent landscape evolving for treatments of periodontal disease? The patent landscape for periodontal disease treatments is shifting towards regenerative therapies and more targeted antimicrobial approaches. Filings include patents for growth factors, peptides, and stem cell-derived therapies aimed at regenerating gum and bone tissue. Concurrently, there is innovation in developing antimicrobial agents with improved specificity to reduce resistance and non-antibiotic approaches that modulate inflammation or disrupt bacterial biofilms.

3. What are the main regulatory differences between a prescription stomatological drug and an over-the-counter (OTC) oral rinse? The main regulatory difference lies in the data required for approval and the level of control over distribution. Prescription drugs require extensive clinical trial data to demonstrate efficacy and safety for specific medical conditions, and they are dispensed under the supervision of a healthcare professional. OTC oral rinses, while also requiring safety and efficacy substantiation, undergo a less rigorous review process, are available directly to consumers, and typically address less severe or symptomatic conditions, such as mild gingivitis or halitosis.

4. Are there emerging technologies in stomatological preparations that aim to address dry mouth (xerostomia) beyond traditional saliva substitutes? Yes, beyond traditional saliva substitutes and stimulators, emerging patent filings are exploring areas such as sustained-release formulations that mimic natural saliva composition over longer periods. This includes mucoadhesive patches or films that can deliver moisturizing agents and electrolytes gradually. Additionally, research is investigating compounds that can stimulate endogenous salivary gland function or enhance the lubrication properties of remaining saliva.

5. How does the increasing awareness of the oral-systemic link influence patenting activity in stomatological preparations? The increasing awareness of the oral-systemic link is driving patenting activity towards preparations that not only treat oral diseases but also aim to mitigate their impact on systemic health. This includes the development of advanced antimicrobial agents for periodontitis that also possess anti-inflammatory properties to reduce systemic inflammatory markers. Patents are also emerging for oral hygiene products that target the oral microbiome in a way that may positively influence systemic inflammatory pathways or reduce bacterial translocation from the oral cavity.

Citations

[1] World Health Organization. (2022). Oral health: Fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/oral-health

[2] Pihlstrom, B. L., Brunsvold, M. A., Newman, M. G., Jimenez, M., & Daneshmand, R. (2005). Periodontal status of U.S. adults in 1999 and 2000. Journal of Periodontology, 76(8), 1349-1355.

[3] United Nations Department of Economic and Social Affairs, Population Division. (2022). World Population Ageing Highlights 2022. Retrieved from https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/publications/world-population-ageing-2022.pdf